Deliver Your News to the World

Philips and University Medical Center Utrecht sign MoU to collaborate on innovations in major disease areas


Philips and University Medical Center Utrecht to develop new solutions for diagnosis, monitoring and treatment of major disease areas including cardiac disease, brain disease and cancer

Royal Philips Electronics (NYSE:PHG, AEX:PHI) today announced that it has signed a memorandum of understanding (MoU) establishing a long-term research partnership with the University Medical Center (UMC) Utrecht, the Netherlands’ largest university hospital. Philips and UMC Utrecht will seek to develop new solutions for the diagnosis, monitoring and treatment of major disease areas.

Philips and UMC will develop collaborative research projects in medical imaging applied to brain disease, cancer, cardiovascular disease, musculoskeletal disease and pulmonary disease. A key area of focus outlined in the MoU is image guided oncology interventions. Philips and UMC Utrecht expect the agreement to result in new treatment methods that will ultimately lead to an improved quality of healthcare delivery.

“High quality healthcare starts with healthcare professionals working together in teams based around their patients,” said Steve Rusckowski, CEO of Philips Healthcare and member of the Board of Management of Royal Philips. “UMC Utrecht and Philips have a long history of working together to develop groundbreaking medical technologies across a wide range of radiology, cardiology, neurology and oncology applications. The secret of our success is our close cooperation. Our people love to work with the team at UMC Utrecht, and their clinicians enjoy benefitting from our research facilities. We want to build on this and to focus on developing solutions throughout the whole cycle of care – from diagnosis to treatment, recovery and follow-up.”

“We’ve signed this MoU with Philips to focus on innovation, patient care and knowledge sharing,” said Professor Geert Blijham, chairman of the Board of UMC Utrecht. “In particular, we will focus on the treatments given to patients, with research principally directed towards translational research – bridging the gap between fundamental scientific research and clinical applications.”


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.